AstraZeneca to conduct comparison between Crestor and Lipitor

LONDON AstraZeneca announced that it will conduct a clinical trial comparing its cholesterol-fighting drug Crestor with Pfizer’s cholesterol drug Lipitor, the world’s best selling drug, according to Reuters.

The new trial, called SATURN, would compare the drugs’ ability to reduce the progression, or induce regression, of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease. Crestor was recently approved by the Food and Drug Administration to fight atherosclerosis.

AstraZeneca said the first of around 1,300 patients in the SATURN trial would be enrolled later this month and the study was expected to complete in 2011.

Lipitor had sales of $12.9 billion, compared to Crestor’s $2 billion in 2006.

Login or Register to post a comment.